表紙
市場調查報告書

移植物抗宿主病 (GVHD) :至2028年的流行病學預測

Graft Versus Host Disease: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 923902
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
移植物抗宿主病 (GVHD) :至2028年的流行病學預測 Graft Versus Host Disease: Epidemiology Forecast to 2028
出版日期: 2020年01月31日內容資訊: 英文 92 Pages
簡介

在主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 移植物抗宿主病 (GVHD) 和確診的發病數量,從2018年的18,408件,到2028年的22,428件,預計AGR (年度成長率) 增加2.18%。

本報告提供全球主要7個國家的移植物抗宿主病 (GVHD) 市場相關調查分析,最新的流行病學預測相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢、過去趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
  • 移植物抗宿主病 (GVHD)的流行病學預測
  • 討論

第4章 附錄

目錄
Product Code: GDHCER229-20

GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

GlobalData epidemiologists utilized historical HSCT data available through country-wide registry reports in the 7MM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, GlobalData epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 7MM had 18,408 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 22,428 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 2.18%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 7MM. In the 7MM, the diagnosed incident cases of aGvHD will increase from 9,786 cases in 2018 to 11,925 cases in 2028, at an Annual Growth Rate (AGR) of 2.19% per year, and the diagnosed incident cases of cGvHD will increase from 8,622 cases in 2018 to 10,503 cases in 2028, at an AGR of 2.18% per year.

Scope

  • Graft Versus Host Disease (GvHD) Epidemiology Report provides an overview of the risk factors and global trends of GvHD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of first allogeneic Hematopoietic stem cell transplantation (HSCT), acute GvHD (aGvHD), and chronic GvHD (cGvHD); diagnosed three-year prevalent cases of aGvHD and cGvHD; and diagnosed incident cases of aGvHD and cGvHD by grade and severity respectively. Additionally, 100-day mortality in aGvHD and one-year mortality cases in cGvHD is also included in this report.
  • The GvHD Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GvHD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global GvHD market.
  • Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the aGvHD grades and cGvHD severity stages that present the best opportunities for GvHD therapeutics in each of the markets covered.
  • Understand magnitude GvHD market by mortality rates and three-year prevalent cases.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Graft-Versus-Host Disease: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 US
    • 3.3.2 5EU
    • 3.3.3 Japan
  • 3.4 Forecast Methodology
    • 3.4.1 Sources Used
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for GvHD (2018-2028)
    • 3.5.1 Incident Cases of First Allogeneic HSCT
    • 3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT
    • 3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT
    • 3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD
    • 3.5.5 Diagnosed Incident Cases of aGvHD by Grade
    • 3.5.6 Diagnosed Incident Cases of cGvHD by Severity
    • 3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD
    • 3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD
    • 3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD
    • 3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors for GvHD

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of GvHD in Diagnosed Incident Cases of First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Incidence of aGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
  • Figure 3: 7MM, Diagnosed Incidence of cGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
  • Figure 4: Case Flow Map of aGvHD and cGvHD
  • Figure 5: Sources Used for First Allogeneic HSCT
  • Figure 6: Sources Used for aGvHD and cGvHD in First Allogeneic HSCT
  • Figure 7: Sources Used for aGvHD Grades
  • Figure 8: Sources Used for cGvHD Severity
  • Figure 9: Sources Used for 100-Day Mortality of aGvHD and One-Year Mortality of cGvHD
  • Figure 10: Sources Used for Three-Year Diagnosed Prevalent Cases of aGvHD and cGvHD
  • Figure 11: 7MM, Diagnosed Incident Cases of First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
  • Figure 12: 7MM, Diagnosed Incident Cases of aGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
  • Figure 13: 7MM, Diagnosed Incident Cases of cGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
  • Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of aGvHD and cGvHD in First Allogeneic HSCT Cases, Men and Women, 2018
  • Figure 15: 7MM, Diagnosed Incident Cases of aGvHD by Grade, Men and Women, All Ages, 2018
  • Figure 16: 7MM, Diagnosed Incident Cases of cGvHD by Severity, Men and Women, All Ages, 2018
  • Figure 17: 7MM, 100-Day Mortality in Diagnosed Incident Cases of aGvHD, Men and Women, All Ages, 2018 and 2028
  • Figure 18: 7MM, One-Year Mortality in Diagnosed Incident Cases of cGvHD, Men and Women, All Ages, 2018
  • Figure 19: 7MM, Three-Year Diagnosed Prevalent Cases of aGvHD, Men and Women, All Ages, 2018
  • Figure 20: 7MM, Three-Year Diagnosed Prevalent Cases of cGvHD, Men and Women, All Ages, 2018